<DOC>
	<DOCNO>NCT02596230</DOCNO>
	<brief_summary>RE-COVERY large , multi-national , multi-center observational study base new data collection . The study enroll characterize patient within 30 day diagnose acute DVT and/or PE . The study two main objective . Objective 1 characterize DVT / PE patient population . All patient DVT and/or PE enrol cross-sectional characterization VTE patient population . Objective 2 compare safety effectiveness dabigatran etexilate regimen treatment VTE comparison VKA regimens . Patients treat dabigatran etexilate VKA follow occurrence outcome event one year .</brief_summary>
	<brief_title>RE-COVERY DVT/PE : Global Study Treatment Secondary Prevention Acute Venous Thromboembolism</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Inclusion criterion : 1 . Written inform consent provide patient accordance local regulation 2 . Diagnosis acute deep vein thrombosis ( DVT ) and/or pulmonary embolism ( PE ) 3 . Age &gt; = 18 year 4 . For Objective 2 , plan anticoagulation therapy least 3 month 5 . For Objective 2 , dabigatran vitamin K antagonist patient available followup data collection Exclusion criterion : 1 . Need anticoagulation therapy condition venous thromboembolism ( VTE ) 2 . Current participation clinical trial VTE indication current use unapproved drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>